As­traZeneca rais­es $200M from its lat­est as­set sale; Austin-based Lung Ther­a­peu­tics rais­es $14M in ven­ture cash

→  As­traZeneca has sold the rights to its mi­grane drug, Zomig for $200 mil­lion up­front and $102 mil­lion in mile­stones. Ger­many-based Grü­nen­thal will gain the rights to mar­ket and sell the drug out­side of Japan. The sale comes as the As­traZeneca is aim­ing to mount a come­back and re­fo­cus on on­col­o­gy, which it em­pha­sized at AS­CO last week­end. In the mean­time, the phar­ma gi­ant has been sell­ing off a string of non-core or dis­ap­point­ing ther­a­pies to raise cash.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN